The evaluation of the knowledge levels and attitudes of medical students who have accomplished obstetric and gynaecological diseases internship in a medical school about human papilloma virus vaccine;Bir tıp fakültesinde kadın hastalıkları ve doǧum stajını yapmış öǧrencilerin HPV aşısı hakkında bilgi düzeyleri ve tutumlarının deǧerlendirilmesi

TAF Preventive Medicine Bulletin

Volumn 10, Issue 5, 2011, Pages 557-564

  Fatih Onsuz M ^a   Topuzoǧlu, Ahmet ^b   Bilgi, Zeynep ^b   Yilmaz, Musa ^b   Amuk, Nagihan ^b   Fahridin, Fevziye ^b  

^a Il Sa lik Müdürlü ü Sakarya   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Attitude; HPV vaccine; Knowledge level; Medical school; Student

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; ATTITUDE TO HEALTH; ATTITUDE TO ILLNESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MEDICAL SCHOOL; MEDICAL STUDENT; SEXUAL INTERCOURSE; STUDENT ATTITUDE; UNSAFE SEX; VACCINATION; WART VIRUS;

EID: 80054883830     PISSN: 1303734X     EISSN: None     Source Type: Journal    
DOI: 10.5455/pmb.20110802053002     Document Type: Article

References (38)

1. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89: 101-105.
2. Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest. 2002; 20: 1080-1085.
3. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527.
4. Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2005; 10: 5-19.
5. Kahn JA, Bernstein DI. Human papillomavirus vaccines. Pediatr Infect Dis J. 2003; 22: 443.
6. Shaw AR. Human papillomavirus vaccines in development: If they're successful in clinical trials, how will they be implemented? Gynecologic Oncology. 2005; 99: S246-248.
7. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-1255.
8. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 1645-1651.
9. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-278.
10. Ault KA. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369: 1861-1868.
11. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 2161-2170.
12. Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine. 2006; 24(3): 122-131.
13. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis. 2000; 27: 49-52.
14. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health. 2005; 37(6): 17-23.
15. Wong LP, Sam IC. Ethnically diverse female university students' knowledge and attitudes toward human papillomavirus (HPV), HPV vaccination and cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2010; 148: 90-95.
16. Esposito S, Bosis S, Pelucchi C, et al. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine. 2007; 25: 6437-6446.
17. Duval B, Gilca V, McNeil S, et al. Vaccination against human papillomavirus: A baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. Vaccine. 2007; 25: 7841-7847.
18. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005; 37: 502-510.
19. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005; 18: 391-398.
20. Aldrich T, Becker D, Garcia SG, Lara D. Mexican physicians' knowledge and attitudes about the human papillomavirus and cervical cancer: a national survey. Sex Transm Infect. 2005; 81: 135-141.
21. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex. Transm. Dis. 2003; 30: 774-778.
22. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006; 117: 1486-1493.
23. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int. J. STD AIDS. 2003; 14: 300-306.
24. De Carvalho NS, Teixeira LM, Pradel EM, Gabardo J, Joly C, Urbanetz AA. Vaccinating against HPV: Physicians' and medical students' point of view. Vaccine. 2009; 27: 2637-2640.
25. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002; 13: 631-639.
26. Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect. 2004; 80: 24-29.
27. Parkin DM, Bray F. Chapter 2: The burden of HPV related cancers. Vaccine. 2006; 24(3); 11-25.
28. Katz IT, Wright AA. Preventing cervical cancer in the developing world. N Engl J Med. 2006; 354: 1110.
29. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 2007; 7: 304.
30. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004; 36: 11-19.
31. Harper DM. Why am I scared of HPV? CA Cancer J Clin. 2004; 54: 245-247.
32. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781-789.
33. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604-615.
34. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37-48.
35. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007: 40; 108-115.
36. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10 to 15 year old adolescents. J Low Genit Tract Dis. 2004: 8; 188-194.
37. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004: 58; 1405-1413.
38. Zimet GD, Mays RM, Sturm LA, Ravert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med. 2005: 159; 132-137.